Enveric Biosciences AI Stock Analysis
Want to see ENVB full AI Analyst Report?
Enveric Biosciences (ENVB) AI Stock Analysis
Enveric Biosciences
(NASDAQ:ENVB)
The score is primarily weighed down by weak financial performance (no revenue, ongoing losses, and continued cash burn despite low debt). Technicals also remain unfavorable with the stock below major moving averages and muted momentum. Valuation offers limited support due to a negative P/E and no dividend, while recent corporate actions add modest governance/capital-structure clarity but do not offset the funding and dilution risks implied by cash flow trends.
Enveric Biosciences (ENVB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.76M
- Dividend Yield
- ―
- Average Volume (3M)
- 72.21K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.04
- Revenue Growth
- ―
- EPS Growth
- 87.05%
- Country
- US
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Enveric Biosciences Business Overview & Revenue Model
Company Description
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101...
Enveric Biosciences Financial Statement Overview
Summary
Overall financials reflect a pre-revenue biotech profile: zero revenue, ongoing losses, and negative gross profit. The main positive is a low-leverage balance sheet with effectively no debt and improved equity versus 2024–2025, but persistent operating and free cash flow burn (TTM burn roughly $8.6M) indicates continued reliance on external funding and potential dilution risk.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -153.92K | -200.86K | -337.49K | -408.03K | -435.20K | -681.61K |
| EBITDA | -8.57M | -8.57M | -9.23M | -16.85M | -19.52M | -55.74M |
| Net Income | -8.73M | -12.13M | -9.57M | ― | -18.50M | -48.98M |
Balance Sheet | ||||||
| Total Assets | 8.94M | 5.10M | 3.08M | 4.30M | 19.55M | 26.72M |
| Cash, Cash Equivalents and Short-Term Investments | 8.30M | 4.68M | 2.24M | 2.29M | 17.72M | 17.36M |
| Total Debt | 0 | 0 | 0 | 0 | 63.82K | 176.30K |
| Total Liabilities | 861.48K | 918.40K | 1.49M | 2.34M | 4.00M | 4.41M |
| Stockholders Equity | 8.08M | 4.18M | 1.59M | 1.96M | 14.67M | 22.31M |
Cash Flow | ||||||
| Free Cash Flow | -8.56M | -8.14M | -7.73M | -14.10M | -17.73M | -12.32M |
| Operating Cash Flow | -8.56M | -8.14M | -7.73M | -14.09M | -17.15M | -11.46M |
| Investing Cash Flow | 0 | 0 | 0 | 11.67K | -584.16K | 2.19M |
| Financing Cash Flow | 14.03M | 10.58M | 7.67M | -1.34M | 18.18M | 24.90M |
Enveric Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENVB, the sentiment is Positive. The current price of 1.49 is above the 20-day moving average (MA) of 1.43, above the 50-day MA of 1.46, and below the 200-day MA of 1.93, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 56.13 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENVB.
Enveric Biosciences Risk Analysis
Enveric Biosciences disclosed 79 risk factors in its most recent earnings report. Enveric Biosciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksEnveric Biosciences Peers Comparison
Overall Rating
INDP51Neutral- ENVB44Neutral
GTBP42Neutral
BDRX41Neutral
ARTL37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| INDP | 51Neutral | $445.39M | -0.46 | -302.75% | ― | ― | 81.43% |
| ENVB | 44Neutral | $6.76M | -0.09 | -168.05% | ― | ― | 87.05% |
| GTBP | 42Neutral | $8.16M | -0.04 | -443.08% | ― | ― | 75.09% |
| BDRX | 41Neutral | $1.29M | -45.20 | -42.42% | ― | ― | 97.97% |
| ARTL | 37Underperform | $1.17M | -0.03 | -519.09% | ― | ― | 59.79% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ENVB | Enveric Biosciences, Inc. | 1.49 | -3.97 | -72.71% | |
| BDRX | Biodexa Pharmaceuticals Plc | 2.40 | -202.00 | -98.83% | |
| INDP | Indaptus Therapeutics, Inc. | 3.21 | 0.25 | 8.45% | |
| GTBP | Gt Biopharma, Inc. | 3.95 | -14.29 | -78.35% | |
| ARTL | Artelo Biosciences | 2.20 | -46.40 | -95.47% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 19, 2026